TEL AVIV, Israel, Sept. 25, 2017 /PRNewswire/ -- CannaTech UK is pleased to announce that MGC Pharma, an Australian based Medical Grade Cannabis company with global operations, will be sponsoring the CannaTech UK Innovation Summit, the first ever conference on Medical Cannabis in the UK.
MGC Pharmaceuticals is a publicly traded (ASX: MXC) BioPharma company with a focus on Phytocannabinoid Medications. MGC Pharma has created a seamless, highly-supervised supply chain, from growing through to API level extraction, with global operations providing proprietary Phytocannabinoid formulations to companies, consumers, researchers and patients worldwide.
MGC Pharma's medications (currently in clinical trials) for treatment areas such as Neurology, Oncology and Palliative Care, all emerge from this pipeline, with the list continuing to grow as more research materializes. With research activities in various fields in Europe, Australia and Israel, MGC Pharma intends to impact global health and wellness via the judicious use of Phytocannabinoid across multiple markets.
CannaTech UK will provide a platform to enable the identification and incubation of world-class innovative solutions for the Cannabis industry. The main event will take place on October 26 at The Old Truman Brewery, and will be preceded on October 25 by a pre-event investor symposium dedicated to understanding the ins-and-outs of investing in the Medical Cannabis industry.
Dr Neubauer and Ron Lipsky from MGC Pharmaceuticals will also be speaking at the conference. Dr Neubauer recently conducted a clinical study to assess the efficacy of a Medical Cannabis formulation in children with treatment-resistant epilepsy. Ron Lipsky is the Manager of Business Development and International Relations at MGC Pharma and has been working for over 10 years in the Medical Cannabis industry, primarily in Israel.
"We are extremely happy to be sponsoring CannaTech UK. As one of the world's leading medical grade Cannabis companies working to improve global health, MGC Pharma sees CannaTech UK as a key venue for reaching the European market, which is poised to grow exponentially, reaching billions of dollars in the next decade. We hope that MGC's speakers will contribute much to both the scientific and financial discourse at the event," said Roby Zomer, CEO & Executive Director of MGC Pharma.
To learn more about the CannaTech UK Innovation Summit, purchase tickets and subscribe to speakers lists & event updates, click here. To learn about iCAN, the Summit's organizers, visit their website here. To learn more about MGC Pharma, visit their website here.
Contact Laura Kam, [email protected], +972-54-806-8613 for further information, to RSVP and to arrange interviews with the conference organizers and speakers.
SOURCE MGC Pharmaceuticals